2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
Histiocytic Sarcoma
National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
13 Active assets in the Histiocytic Sarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PAN-FGFR TYROSINE KINASE INHIBITOR JNJ-42756493 National Cancer Institute (NCI) | Phase 2 | CCC |
Palbociclib National Cancer Institute (NCI) | Phase 2 | CCC |
Pembrolizumab Dana-Farber Cancer Institute | Phase 2 | CCC |
Ulixertinib National Cancer Institute (NCI) | Phase 2 | CCC |
Olaparib National Cancer Institute (NCI) | Phase 2 | CCC |
View all 14 →
Same molecule, other indications
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →